APGE insider transaction filings
Apogee Therapeutics, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-03. Screen APGE transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 17 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 5 legs across 5 filings by 2 insiders — 137,400 shares, $18,244,445 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 56.
- Largest priced transaction: sale of 80,000 shares @ $132.54 ($10,603,200) by HENDERSON MICHAEL THOMAS, filed 2026-06-24.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| HENDERSON MICHAEL THOMAS — Chief Executive Officer, Director | 3 | — | 2 legs · 100,000 sh · $13,275,800 | 5 |
| Dambkowski Carl — Chief Medical Officer | 5 | — | 3 legs · 37,400 sh · $4,968,645 | 10 |
| Fairmount Funds Management LLC — Director & Fairmount Healthcare Fund II L.P. — Director & Kiselak Tomas — Director & Harwin Peter Evan — Director | 2 | — | — | 12 |
| Shah Nimish P — Director | 1 | — | — | 7 |
| Henderson Jane — Chief Financial Officer | 2 | — | — | 5 |
| McKenna Mark C. — Director | 1 | — | — | 5 |
| Bollinger Lisa — Director | 1 | — | — | 4 |
| Fox Jennifer A. — Director | 1 | — | — | 4 |
| JONES WILLIAM A JR — Director | 1 | — | — | 4 |
Recent Form 4 filings — Apogee Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-03 | 4 | Dambkowski Carl — Chief Medical Officer | Disposition to issuer (D): 1,375 @ $135.06 · Disposition to issuer (D): 167,123 · Disposition to issuer (D): 110,665 (derivative) · Disposition to issuer (D): 124,962 (derivative) · Disposition to issuer (D): 83,690 (derivative) | EDGAR |
| 2026-09-03 | 4 | Bollinger Lisa — Director | Disposition to issuer (D): 18,550 (derivative) · Disposition to issuer (D): 8,112 (derivative) · Disposition to issuer (D): 14,461 (derivative) · Disposition to issuer (D): 7,657 (derivative) | EDGAR |
| 2026-09-03 | 4 | Fox Jennifer A. — Director | Disposition to issuer (D): 34,824 · Disposition to issuer (D): 10,370 (derivative) · Disposition to issuer (D): 14,461 (derivative) · Disposition to issuer (D): 7,657 (derivative) | EDGAR |
| 2026-09-03 | 4 | HENDERSON MICHAEL THOMAS — Chief Executive Officer, Director | Disposition to issuer (D): 920,941 · Disposition to issuer (D): 387,012 (derivative) · Disposition to issuer (D): 357,036 (derivative) · Disposition to issuer (D): 253,016 (derivative) | EDGAR |
| 2026-09-03 | 4 | McKenna Mark C. — Director | Disposition to issuer (D): 20,000 · Disposition to issuer (D): 150,000 (derivative) · Disposition to issuer (D): 10,370 (derivative) · Disposition to issuer (D): 14,461 (derivative) · Disposition to issuer (D): 7,657 (derivative) | EDGAR |
| 2026-09-03 | 4 | Shah Nimish P — Director | Disposition to issuer (D): 1,750,000 @ $135.11 · Disposition to issuer (D): 6,743,321 (derivative) @ $135.11 · Disposition to issuer (D): 47,758 (derivative) · Disposition to issuer (D): 10,370 (derivative) · Disposition to issuer (D): 14,461 (derivative) · Disposition to issuer (D): 7,657 (derivative) · +1 more | EDGAR |
| 2026-09-03 | 4 | Henderson Jane — Chief Financial Officer | Disposition to issuer (D): 158,371 · Disposition to issuer (D): 175,345 (derivative) · Disposition to issuer (D): 124,962 (derivative) · Disposition to issuer (D): 83,690 (derivative) | EDGAR |
| 2026-09-03 | 4 | JONES WILLIAM A JR — Director | Disposition to issuer (D): 34,824 · Disposition to issuer (D): 10,370 (derivative) · Disposition to issuer (D): 14,461 (derivative) · Disposition to issuer (D): 7,657 (derivative) | EDGAR |
| 2026-09-03 | 4 | Fairmount Funds Management LLC — Director Fairmount Healthcare Fund II L.P. — Director Kiselak Tomas — Director Harwin Peter Evan — Director | Disposition to issuer (D): 340,855 · Disposition to issuer (D): 51,166 · Disposition to issuer (D): 51,166 · Disposition to issuer (D): 6,743,321 (derivative) · Disposition to issuer (D): 47,758 (derivative) · Disposition to issuer (D): 10,370 (derivative) · +2 more | EDGAR |
| 2026-08-11 | 4 | Fairmount Funds Management LLC — Director Fairmount Healthcare Fund II L.P. — Director Kiselak Tomas — Director Harwin Peter Evan — Director | Option exercise (M): 31,838 @ $17 · Option exercise (M): 10,370 @ $43.85 · Option exercise (M): 31,838 (derivative) @ $0 · Option exercise (M): 10,370 (derivative) @ $0 | EDGAR |
| 2026-08-07 | 4 | Dambkowski Carl — Chief Medical Officer | Option exercise (M): 4,125 @ $22.86 · Sale (S): 5,500 @ $134.17 · Option exercise (M): 4,125 (derivative) @ $0 | EDGAR |
| 2026-07-24 | 4 | Henderson Jane — Chief Financial Officer | Gift (G): 15,000 @ $0 | EDGAR |
| 2026-07-16 | 4 | Dambkowski Carl — Chief Medical Officer | Gift (G): 8,000 @ $0 | EDGAR |
| 2026-07-10 | 4 | HENDERSON MICHAEL THOMAS — Chief Executive Officer, Director | Sale (S): 20,000 @ $133.63 · Gift (G): 75,046 @ $0 | EDGAR |
| 2026-07-02 | 4 | Dambkowski Carl — Chief Medical Officer | Option exercise (M): 4,125 @ $22.86 · Sale (S): 5,500 @ $132.74 · Option exercise (M): 4,125 (derivative) @ $0 | EDGAR |
| 2026-06-24 | 4 | Dambkowski Carl — Chief Medical Officer | Sale (S): 26,400 @ $132.60 | EDGAR |
| 2026-06-24 | 4 | HENDERSON MICHAEL THOMAS — Chief Executive Officer, Director | Sale (S): 80,000 @ $132.54 | EDGAR |
| 2026-06-12 | 4 | HENDERSON MICHAEL THOMAS — Chief Executive Officer, Director | Sale (S): 6,770 @ $82.21 · Sale (S): 7,654 @ $82.78 · Sale (S): 1,080 @ $84.18 · Sale (S): 1,577 @ $85.19 · Sale (S): 2,305 @ $86.27 · Sale (S): 614 @ $86.89 | EDGAR |
| 2026-06-11 | 4 | Bollinger Lisa — Director | Grant/award (A): 7,657 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Fox Jennifer A. — Director | Grant/award (A): 7,657 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Fairmount Funds Management LLC — Director Kiselak Tomas — Director | Grant/award (A): 7,657 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | McKenna Mark C. — Director | Grant/award (A): 7,657 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Shah Nimish P — Director | Grant/award (A): 7,657 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | JONES WILLIAM A JR — Director | Grant/award (A): 7,657 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Dambkowski Carl — Chief Medical Officer | Option exercise (M): 4,125 @ $22.86 · Sale (S): 5,500 @ $78.71 · Option exercise (M): 4,125 (derivative) @ $0 | EDGAR |
| 2026-05-15 | 4 | HENDERSON MICHAEL THOMAS — Chief Executive Officer, Director | Sale (S): 18,659 @ $82.05 · Sale (S): 1,341 @ $82.58 | EDGAR |
| 2026-05-08 | 4 | Dambkowski Carl — Chief Medical Officer | Option exercise (M): 4,125 @ $22.86 · Sale (S): 3,700 @ $83.92 · Sale (S): 1,800 @ $84.60 · Option exercise (M): 4,125 (derivative) @ $0 | EDGAR |
| 2026-05-04 | 4 | Henderson Jane — Chief Financial Officer | Sale (S): 811 @ $81.02 · Sale (S): 900 @ $82.60 · Sale (S): 289 @ $83.16 | EDGAR |
| 2026-04-20 | 4 | HENDERSON MICHAEL THOMAS — Chief Executive Officer, Director | Option exercise (M): 3,000 @ $22.86 · Option exercise (M): 3,000 (derivative) @ $0 | EDGAR |
| 2026-04-17 | 4 | Henderson Jane — Chief Financial Officer | Sale (S): 2,000 @ $90 | EDGAR |
| 2026-04-10 | 4 | HENDERSON MICHAEL THOMAS — Chief Executive Officer, Director | Sale (S): 17,800 @ $82.48 · Sale (S): 2,000 @ $83.26 · Sale (S): 200 @ $85 | EDGAR |
| 2026-04-03 | 4 | Dambkowski Carl — Chief Medical Officer | Option exercise (M): 4,125 @ $22.86 · Sale (S): 2,698 @ $84.31 · Sale (S): 2,702 @ $85.33 · Sale (S): 100 @ $85.89 · Option exercise (M): 4,125 (derivative) @ $0 | EDGAR |
| 2026-04-03 | 4 | Henderson Jane — Chief Financial Officer | Sale (S): 900 @ $84.46 · Sale (S): 1,100 @ $85.46 | EDGAR |
| 2026-03-27 | 4 | Henderson Jane — Chief Financial Officer | Sale (S): 2,000 @ $85 | EDGAR |
| 2026-03-13 | 4 | HENDERSON MICHAEL THOMAS — Chief Executive Officer, Director | Sale (S): 8,363 @ $74.29 · Sale (S): 8,219 @ $74.83 · Sale (S): 3,418 @ $75.86 | EDGAR |
| 2026-03-06 | 4 | Dambkowski Carl — Chief Medical Officer | Option exercise (M): 4,125 @ $22.86 · Sale (S): 3,225 @ $70.33 · Sale (S): 2,075 @ $71.98 · Sale (S): 200 @ $73.26 · Option exercise (M): 4,125 (derivative) @ $0 | EDGAR |
| 2026-03-04 | 4 | Henderson Jane — Chief Financial Officer | Sale (S): 300 @ $68.27 · Sale (S): 300 @ $69.43 · Sale (S): 994 @ $70.45 · Sale (S): 406 @ $71.66 | EDGAR |
| 2026-02-13 | 4 | HENDERSON MICHAEL THOMAS — Chief Executive Officer, Director | Sale (S): 11,494 @ $62.96 · Sale (S): 7,551 @ $63.73 · Sale (S): 955 @ $64.99 | EDGAR |
| 2026-02-04 | 4 | Dambkowski Carl — Chief Medical Officer | Option exercise (M): 4,125 @ $22.86 · Sale (S): 2,481 @ $64.88 · Sale (S): 1,420 @ $65.83 · Sale (S): 1,299 @ $66.85 · Sale (S): 100 @ $67.88 · Sale (S): 200 @ $68.94 · +1 more | EDGAR |
| 2026-02-04 | 4 | Henderson Jane — Chief Financial Officer | Sale (S): 792 @ $65.21 · Sale (S): 1,108 @ $66.15 · Sale (S): 100 @ $66.89 | EDGAR |
| 2026-01-22 | 4 | Fairmount Funds Management LLC — Director Fairmount Healthcare Fund II L.P. — Director Kiselak Tomas — Director Harwin Peter Evan — Director | Sale (S): 1,750,000 @ $76.30 | EDGAR |
| 2026-01-16 | 4 | HENDERSON MICHAEL THOMAS — Chief Executive Officer, Director | Sale (S): 1,440 @ $78.64 · Sale (S): 8,476 @ $79.82 · Sale (S): 2,374 @ $81 · Sale (S): 1,854 @ $82.41 · Sale (S): 5,386 @ $83.16 · Sale (S): 470 @ $83.79 | EDGAR |
| 2026-01-09 | 4 | Dambkowski Carl — Chief Medical Officer | Option exercise (M): 14,025 @ $22.86 · Sale (S): 2,954 @ $77.13 · Sale (S): 14,820 @ $77.90 · Sale (S): 826 @ $79.04 · Sale (S): 100 @ $80.06 · Option exercise (M): 14,025 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Dambkowski Carl — Chief Medical Officer | Grant/award (A): 83,690 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | HENDERSON MICHAEL THOMAS — Chief Executive Officer, Director | Grant/award (A): 253,016 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Henderson Jane — Chief Financial Officer | Sale (S): 1,920 @ $74.13 · Sale (S): 4,080 @ $75.20 · Sale (S): 2,000 @ $80 · Grant/award (A): 83,690 (derivative) @ $0 | EDGAR |
| 2025-12-23 | 4 | Henderson Jane — Chief Financial Officer | Sale (S): 1,500 @ $80 | EDGAR |
| 2025-12-12 | 4 | HENDERSON MICHAEL THOMAS — Chief Executive Officer, Director | Sale (S): 9,435 @ $74.88 · Sale (S): 10,005 @ $75.79 · Sale (S): 560 @ $76.58 | EDGAR |
| 2025-12-05 | 4 | HENDERSON MICHAEL THOMAS — Chief Executive Officer, Director | Sale (S): 40,000 @ $75.01 | EDGAR |
| 2025-12-05 | 4 | Henderson Jane — Chief Financial Officer | Sale (S): 1,500 @ $75 | EDGAR |
Recent 8-K events — Apogee Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-03 | 8-K | 1.02 — Termination of a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-11 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-08-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-22 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-22 | 8-K | 1.01 — Entry into a Material Definitive Agreement 5.07 — Submission of Matters to a Vote of Security Holders 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-12 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-27 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-27 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-24 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=APGE returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →